More than 1.23 mln Russians have passed tests for antibodies to the coronavirus in Invitro’s laboratories, with some 25% of them testing positive, the Russian medical company said on Wednesday.
“By now, more than 1.23 mln coronavirus tests have been conducted, while the total number of positive results hits 25.1% in Russia,” the medical company stated.
The biggest number of “cases” per day was recorded in Novosibirsk, Siberia, where the positive tests’ share for G-class antibodies in December exceeded 60%. In another Siberian city of Krasnoyarsk, the figure was 58%, in Omsk – 56%, in Barnaul – 55% and in Irkutsk – 54%.
The epidemiological situation in the largest cities in the Urals follows the same pattern. On average, 52% of daily tests returned positive in Yekaterinburg and Surgut, 53% – in Tyumen and 57% – in Chelyabinsk and Magnitogorsk.
However, the figures differ in Russia’s largest cities of Moscow and St. Petersburg. In Moscow, only 17.7% out of more than 286,000 tests having been conducted since May confirmed the presence of antibodies, while the share of positive tests last month was 30%.
In St. Petersburg, the total number of COVID-19 tests surpassed 101,000, and the share of positive results since May was 25%, while last month (on average per day) it reached 38%.
The Invitro medical company launched mass testing for coronavirus antibodies across Russia on May 18, 2020. Laboratory studies to detect G-class antibodies (IgG) to a past infection use venous blood serum.
Invitro, Russia’s private medical company specializing in laboratory diagnostics and medical services, was founded in 1995. The company has offices in six countries with eight laboratory complexes that carry out more than 150,000 studies per day.
Work on 26 coronavirus vaccine options is underway in Russia, Head of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing Anna Popova said at a meeting of the sanitary watchdog chiefs from BRICS countries.
“Work on 26 vaccine options is underway at 17 research centers,” she pointed out.
Russia has so far registered two domestic coronavirus vaccines, one of which was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology and the other one by the State Research Center of Virology and Biotechnology Vector.
A third vaccine, developed by the Russian Academy of Sciences’ Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, may be registered in the near future.
Header: MOSCOW, RUSSIA – A nurse arranging test tubes with blood samples for COVID-19 antibody testing at Moscow’s City Hospital No 175. Starting May 15, Moscow launched a large-scale free program for coronavirus antibody testing. Gavriil Grigorov/TASS